Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: A phase II trial of the NSABP foundation research group

Clinical Breast Cancer

Volumn 11, Issue 4, 2011, Pages 228-234

  Rastogi, Priya ^a,b   Buyse, Marc E ^c   Swain, Sandra M ^a,d   Jacobs, Samuel A ^a,b   Robidoux, André ^a,e   Liepman, Marcia K ^a,f   Pajon, Eduardo R ^a,g   Dy, Philip A ^a,h,i   Posada Jr , Juan G ^a,j   Melnik, Marianne K ^a,k   Piette, Fanny ^c   Geyer Jr , Charles E ^a,l   Mamounas, Elfetherios P ^a,m   Wolmark, Norman ^a,l  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^d WASHINGTON CANCER INSTITUTE   (United States)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f West Michigan Cancer Center   (United States)

^g Colorado Cancer Research Program ^*  (United States)

^h Cancer Care Specialists of Central Illinois   (United States)

ⁱ Decatur Memorial Hospital   (United States)

^j SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^k GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM   (United States)

^l ALLEGHENY GENERAL HOSPITAL   (United States)

^m Aultman Health Foundation   (United States)

more..

Author keywords

Locally advanced breast cancer; Neoadjuvant chemotherapy; Preoperative chemotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEADACHE; HEARTBURN; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; INFLAMMATORY BREAST CANCER; LEUKOPENIA; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PREOPERATIVE CARE; PREOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SYSTOLIC DYSFUNCTION; TASTE AVERSION; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

EID: 80052693599     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.04.001     Document Type: Article

References (13)

1. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
2. D. Miles, A. Chan, and L.Y. Dirix Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2negative metastatic breast cancer J Clin Oncol 28 2010 3239 3247
3. N.J. Miles, V. Diéras, and J. Glaspy RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 10 2011 1252 1260
4. E.A. Perez, D.W. Hillman, and T. Dentchev North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer Ann Oncol 21 2010 269 274
5. S.B. Wedam, J.A. Low, and S.X. Yang Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer J Clin Oncol 24 2006 769 777 (Pubitemid 46622044)
6. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
7. D.J. Sargent, V. Chan, and R.M. Goldberg A three-outcome design for phase II clinical trials Control Clin Trials 22 2001 117 125 (Pubitemid 32289448)
8. I. Makhoul, K.S. Vicki, and S. Korourian Bevacizumab combined with chemotherapy significantly improves pathologic complete response in patients with operable or locally advanced breast cancer 2008 Abstracts: Cancer Res 69 suppl2 2009 335s Abstract 5114
9. R. Greil, M. Moik, and R. Reitsamer Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: efficacy and safety in a phase II pilot study Eur J Surg Oncol 35 2009 1048 1054
10. M.R. Mancuso, R. Davis, and S.M. Norberg Rapid vascular regrowth in tumors after reversal of VEGF inhibition J Clin Invest 116 2006 2610 2621 (Pubitemid 44511625)
11. W. Cacheux, T. Boisserie, and L. Staudacher Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery Ann Oncol 19 2008 1659 1661
12. N. Wolmark, G. Yothers, and M.J. O'Connell A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08 J Clin Oncol 27 suppl 2009 18 abstract LBA4 http://www.asco.org Accessed April 27, 2011
13. L.A. Korde, L. Lusa, and L. McShane Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer Breast Cancer Res Treat 119 2010 685 699